Despite the unheralded success of immune checkpoint blockade in delivering durable responses for some patients with nonsmall-cell lung cancer (NSCLC), the majority of patients do not respond. PD-L1 tumour expression and pre-existing tumour T-cell infiltration have been correlated with improved clinical outcomes to anti-PD-1/anti-PD-L1. However, patients with tumours that are negative for PD-L1 expression can also respond to treatment. Strategies to combine other treatment modalities like radiotherapy (RT) with immune checkpoint inhibitors are being investigated as means of improving the response rates to PD-1/PD-L1 antibody blockade. RT induces immunogenic changes in cancer cells, can adaptively upregulate tumour cell PD-L1 expression and can improve the efficacy of anti-PD-1/anti-PD-L1 therapy. How we design future clinical trials in NSCLC also depends on practical considerations of delivering these treatment combinations, such as RT dose, fractionation and field volume, as well as scheduling with immune checkpoint blockade. Here, we review reasons for resistance to anti-PD-1/anti-PD-L1 and how RT may be utilised in combination with these drugs to enhance their effect by building better translational research platforms.
Introduction
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer mortality worldwide. Radiotherapy (RT) alone or in combination with chemotherapy plays a major role in the management of early and locally advanced NSCLC and is known to improve longterm survival by enhancing local disease control [1] . Recently, the immune checkpoint inhibitors (ICIs) anti-programmed death-1 (anti-PD-1) antibodies pembrolizumab and nivolumab have achieved objective response rates (ORRs) of around 20% in advanced NSCLC, which is otherwise treated with cytotoxic chemotherapies [2] [3] [4] [5] [6] . These response rates can be increased to around 40% by combining PD-1 blockade with T-lymphocyte-associated antigen 4 (CTLA-4) blockade [7] , highlighting the need to develop appropriate combinations of therapy with ICIs to improve their efficacy. RT immunologically modifies the tumour microenvironment (TME), including enhanced antigen presentation and upregulation of tumour programmed death ligand-1 (PD-L1) expression [8, 9] .
When RT is combined with anti-PD-1 antibody, durable responses have been seen in primary and secondary tumours in preclinical studies [8] [9] [10] . Recently, durvalumab (anti-PD-L1 antibody) administered following definitive chemoradiation (CRT) in a phase III trial of locally advanced NSCLC patients unselected for PD-L1 showed an 11-month improvement of progression-free survival (PFS) compared with placebo [11] . Along with its limited systemic toxicities, RT therefore represents an attractive agent to combine with ICIs.
Why do the majority of patients fail to respond to immune checkpoint blockade?
Tumour cell PD-L1 expression has been postulated as a predictive biomarker [4, 6, 12, 13] , however, response rates remain below 60% even in patients expressing higher levels of PD-L1 [6] . Furthermore, PD-L1-low or PD-L1-negative tumours can still show some response to anti-PD-1/anti-PD-L1 [12, 13] . Varying PD-L1 immunohistochemistry assays used within clinical trials (e.g. Dako versus Ventana assays) have led to conflicting results as regards to PD-L1 status, with use of different test antibody clones, protocols, scoring systems, and threshold cut-offs for positivity [14] . Thus, consideration and standardisation of the heterogeneity of PD-L1 expression on both tumours and immune cells in the TME is urgently required [15] . Furthermore, the impact of PD-L2 expression, a ligand that shares affinity for PD-1 on T cells with PD-L1, is less well understood [15] . Consequently, PD-L1 alone is probably not a reliable predictive biomarker, and multiple dynamic factors during tumour evolution and the development of treatment resistance need to be considered.
The 'cancer immunogram' framework developed by Blank et al. implies that critical to every tumour response remains increased effector T-cell (T eff ) activity. Feeding into this are several dynamic biomarker parameters that may help direct personalised immunotherapeutic approaches. These include T-cell infiltrate and functionality, major histocompatibility complex (MHC) expression status, neoantigen burden, metabolic status, and general immune status factors (such as lymphocyte count) [16] . Non-responders to ICIs can be further simplified into patients who have reduced tumour-specific somatic mutational burden, defects in antigen recognition machinery (MHC expression) and/or increased immunosuppressive factors within the TME (Table 1) . If a tumour exhibits high mutational burden but MHC is downregulated or the TME remains suppressive (theoretical patients 1 and 2, Table 1 ), an effective immune response will not ensue. Equally, if the right balance of immune cell populations, checkpoint molecules and antigen recognition machinery are present, but a tumour has a low neoantigen burden to begin with, treatment resistance is likely (theoretical patient 3, Table 1 ). Simplification of barriers to ICI response can provide a framework with which to therapeutically manipulate these factors.
Reduced TIL infiltration or activity
The presence of CD8þ tumour-infiltrating lymphocytes (TILs) is widely recognised as a positive prognostic indicator across multiple solid malignancies [17] [18] [19] . Additionally, ratios of CD8þ to T-regulatory cells (Tregs) have proved helpful in predicting favourable treatment responses [19] . More recently, less studied gamma-delta (cd) T cells have been identified to secrete high levels of IFN-c and IL-17, and possess both antitumour (IFN-c dominated) and pro-tumour (IL-17 dominated) effects [20] . cd T cells have been adoptively transferred in a phase I study of NSCLC with encouraging results [21] . Nevertheless, the potential opposing functions of this T-cell subset complicates the milieu of TILs that may populate the TME and requires further investigation to further understand the relative importance of this T-cell subset.
Even when TILs are present within the TME they can become dysfunctional or develop an exhausted phenotype, failing to eradicate or control tumours [22] . This may occur following interruption to CD8þ T-cell transcriptional machinery and/or via the accumulation of inhibitory checkpoint molecules, such as PD-1 which act to dampen T eff activity [22] . Furthermore, a recent melanoma study demonstrated that even when anti-PD-1 resulted in T-cell reinvigoration, this was clinically ineffective where tumour burden was high [23] . Further investigation of T-cell exhaustion (T ex ) thresholds and correlation with other TILs is required to understand limitations to anti-PD-1-mediated T-cell reinvigoration.
Increased tumour infiltration of suppressive immune cell populations
One of the most pressing challenges is the need to establish reliable quantitative validated platforms that provide detailed data on the predominant immune effector cell populations promoting anti-and pro-tumour activity across different cancer types. Clinical trials of ICIs have relied on theoretical assumptions to increase tumour control via promoting T-cell activity. However, if non-T-cell lineage populations dominate the TME in the first instance, ICIs will fail to have the desired effect. Recently, neutrophils were identified to dominate the immune contexture of surgically resected clinical NSCLC specimens (20% of all CD45þ immune cells), with higher levels in squamous versus nonsquamous histological subtypes [24] . Squamous samples also contained elevated levels of Tregs and PD-1þ T cells compared with adenocarcinomas [24] . Tumour-associated neutrophils and macrophages are relatively understudied suppressive immune cell populations that may have more impact on the TME than previously thought, and could potentially be therapeutically targeted in combination with ICIs.
Imbalance of immune checkpoints
Immune checkpoints maintain T-cell homeostasis by ensuring a dynamic balance of T-cell activated immune responses against self-tolerance and protection of host tissues. During tumour evolution, upregulation of inhibitory checkpoint molecules results in reduced immunogenicity and unregulated tumour growth. In clinical and preclinical NSCLC studies of PD-L1 positive tumours failing to respond to anti-PD-1/anti-PD-L1, upregulation of additional inhibitory molecules to PD-1 are seen and result in varying degrees of T-cell dysfunction [25, 26] . Notably, T-cell immunoglobulin mucin-3 (Tim-3) has been demonstrated to upregulate on PD-1-positive T cells in a preclinical model of NSCLC and the addition of anti-Tim-3 with anti-PD-1 improved survival in this [26] . Additionally, accumulating coexpression of Tim-3, CTLA-4, lymphocyte-activated gene-3 (Lag-3) and B-and T-lymphocyte attenuator have been observed on T cells of patients with more progressive NSCLC, and these T cells exhibit increasingly exhausted phenotypes [25] . Therapeutically targeting multiple checkpoint molecules has shown enhanced tumour control in preclinical models [27] [28] [29] . Anti-CTLA-4 and anti-PD-1 have displayed improved ORRs of around 50% in patients with advanced melanoma [30] and NSCLC [7] . However, it remains unclear as to which T ex populations can be reinvigorated by multiple ICIs. In addition to removing constraints on T-cell priming and activation with ICIs, costimulatory checkpoint molecules such as OX40 can also be targeted to help accelerate immune responses. However, caution is required in combining immunotherapies that may have different mechanisms of action. Whilst sequential anti-OX40 followed by anti-PD-1 antibodies demonstrated preclinical tumour regression, concurrent or the reverse order of sequential drug combination had adverse effects on anti-OX40-mediated responses [31] . This highlights the need to consider timing and sequence of multiple drugs or treatment modalities when designing studies.
Low neoantigen burden
Tumour cells accumulate non-synonymous somatic mutations that are considered as non-self and can thus be recognised by the immune system as neoantigens. Most melanoma and NSCLC cases develop following exposure to mutagens (ultraviolet light and tobacco smoke, respectively), and therefore display some of the highest neoantigen loads across all cancer types [32, 33] . Somatic mutational and neoantigen burden correlates with clinical response to ICIs in both melanoma [34] and NSCLC [33] . Furthermore, mismatch repair-deficient tumours, which encompass higher levels of genomic instability and tumour-specific mutations, display improved response to anti-PD-1 [35] . Patients with NSCLC who have never smoked, including those with epidermal growth factor receptor and anaplastic lymphoma kinase mutations exhibit low levels of mutational burden and poor response to ICIs [36] . Nevertheless, high mutational burden does not necessarily lead to clinical responses to ICIs and other factors appear important such as reduced TIL infiltration or T-cell effector activity and/or reduced neoepitope-MHC-I binding. Neoantigen heterogeneity may also predict clinical response to checkpoint blockade. Mcgranahan et al. demonstrated that patients with clonal (trunk) versus subclonal (branch) neoantigens had more durable clinical response to ICIs in metastatic melanoma and NSCLC [37] . Additionally, some chemotherapytreated patients exhibited more heterogeneous subclonal neoantigens and worse outcome [37] . However, some of these patients were only exposed to the alkylating agent dacarbazine, which although can stimulate natural killer (NK) cell activity, may not drive dendritic cell (DC) antigen processing or directly elicit an effective CD8þ T-cell response [38] .
Downregulated tumour MHC expression
MHC-I can be downregulated by tumour cells, resulting in reduced CD8þ T-cell recognition [39, 40] . This represents a significant obstacle to T-cell-based immunotherapies as even in the presence of high-neoantigen load, a lack of appropriate antigenrecognition machinery is likely to result in poor clinical responses (Table 1) . Downregulation and loss of MHC-I is a multi-stage process: initial loss of one HLA class I haplotype can occur during early tumour progression, allowing a period of tumour cell 'escape' via immunoediting. Subsequently, total loss of HLA class I expression can occur via transcriptional downregulation of antigen processing machinery and HLA class I heavy genes. This gives rise to more oncogenic and proliferative tumour cells [41] . Some tumour cells may at least partially respond to exogenous cytokine stimulation (namely interferon-gamma (IFN-c)) to reconstitute MHC-I antigen processing and presentation [42] . Interestingly, upregulation of tumour PD-L1 expression is IFNc-dependent [43] , and the relative importance of MHC-I and PD-L1 upregulation to clinical responsiveness is currently not understood. By inference, checkpoint blockade would therefore still be required even when MHC-I expression has been restored and upregulated.
Tumour metabolic status
The term 'metabolic checkpoints' has recently been coined to describe how changes in tumour metabolism may determine the immunological response. Tumour cells are heavily glucoseconsuming and quickly develop alternative metabolic programmes, switching to glycolysis. Anaerobic metabolism gives rise to directly immunosuppressive metabolites such as lactate and reduction of glucose within the TME can cause T eff anergy and cancer progression [44] . Additionally, T eff differentiation is heavily reliant on mechanistic target of rapamycin (mTOR) signalling [45, 46] . The upregulation of PD-1 on T cells also prevents their glucose and glutamine uptake and increases fatty acid oxidation, leading to their dormancy [47] . In a KRAS model of NSCLC, Kras copy gains resulted in phenotypically distinct genotypes, with an increase in glycolysis in homozygous tumours [48] . These cells could be therapeutically targeted with a glucose analogue [48] .
Hypoxia-inducible-factor-alpha (HIF1-a) is a transcription factor encoding enzymes, proteins and transporters within the glycolysis and pentose phosphate pathways. Its pathological upregulation in hypoxic conditions supports tumour angiogenesis and growth [49] and can increase proportions of Tregs within the TME [50] and induce tumour cell PD-L1 upregulation [51] . Additionally, indoleamine 2,3-dioxygenase (IDO) is an enzyme that converts the amino acid tryptophan to kynurenine, and is upregulated in a variety of cancers constitutively or upon exposure to IFN-c [52] , including in lung cancer [53] . Resulting depletion of tryptophan in IDO-upregulated cancers can cause T-cell anergy [54] and inhibitors of IDO have demonstrated antitumour activity in preclinical studies [55, 56] .
RT may lead to immunogenic cell death
RT can modify the TME and increase the immunogenicity of tumour cells by enhancing MHC-I, NK cell ligand, and Fas surface expression, increasing tumour antigen and type I IFN release, stimulating complement deposition, and inducing immunogenic cell death (ICD) [57] . The stimulator of IFN pathway is implicated in the cross priming of CD8þ T cells following RT [58] . Additionally, ICD involves the release of damage-associated molecular patterns, namely calreticulin, high motility group box-1 and adenosine triphosphate, which enable DC activation and T-cell cross-priming. In this fashion, RT can immunologically prime the TME, whilst minimising systemic toxicities. When RT is combined with systemic ICIs, this immune priming signal can be translated into systemic immune tumour control, known as the abscopal effect. Abscopal responses have been seen in preclinical models of breast cancer combining anti-CTLA-4 with RT [59, 60] . Additionally, they have been observed in a few patient cases of advanced melanoma [61] [62] [63] [64] and NSCLC [65] combining ipilimumab (anti-CTLA-4) with RT; the latter being a tumour type in which ipilimumab has very little efficacy alone.
The potential effects of RT on the TME RT can enhance TIL repertoire RT has been known to indirectly increase TIL frequency in preclinical models of melanoma and pancreatic cancer by inducing type-I interferons and favourable macrophage differentiation into an M1 phenotype [66, 67] (Figure 1 ). Various doses of radiation of up to 15 Gy induced TIL infiltration in these models. Interestingly, Crocenzi et al. found that hypofractionated RT (versus fractionated RT) in locally advanced and borderline resectable pancreatic cancer was less lympho-depleting, with enhanced tumour infiltration of CD3þ and CD8þ T cells [68] . Nonetheless, few TIL studies have reported on the full spectrum of T lymphocytes (CD3þ, CD4þ, CD8þ, and FoxP3þ) or utilised TIL ratios to better quantify and relate these differing populations, nor is there standardisation in the methods for doing so [19] .
RT has additionally been demonstrated to modify the T-cell repertoire, enriching the top 0.01% of expanding T-cell receptor (TCR) clones in a preclinical model of melanoma [69] and in human head and neck cancers treated with CRT [70] . Furthermore, in a murine colorectal model, fractionated RT has been shown to drive a polyclonal T-cell response, predominantly arising from the expansion of pre-existing clones within the TME [9] . Interestingly, combination of RT with anti-PD-1 increased TCR repertoire concordance and clonal overlap between irradiated and non-irradiated tumours, resulting in an abscopal response [9] . Given that TCR diversity correlates with clinical response to ipilimumab [71] [72] [73] , it seems plausible that using combinations of treatments that enrich TCR diversity may enhance the proportion of responders to checkpoint blockade (Figure 1) . The potential clinical relevance of oligoclonal expansion of just CD8þ T cells, or expansion of several types of CD4þ and CD8þ T cells is currently uncertain.
RT can lead to adaptive upregulation of PD-L1
Single dose and fractionated RT can upregulate tumour PD-L1 expression in preclinical models of colorectal cancer and NSCLC [8, 10, 43] . Administration of anti-PD-1 antibody concurrently with RT is able to overcome this adaptive upregulation of PD-L1 and restore long-term tumour control [8, 10, 43] . An intriguing possibility is that RT could be used to increase both the necessary antigen recognition machinery (MHC-I expression) and the magnitude of anti-PD-L1 antibodies binding to tumour cells (Figure 1 ). RT in combination with anti-CTLA-4 has demonstrated improved clinical outcomes in patients with metastatic melanoma [61] [62] [63] [64] and in one patient with NSCLC [65] . Efficacies of anti-PD-1/anti-PD-L1 in combination with RT remain to be demonstrated in clinical trials but have revealed improved tumour control in preclinical studies of colorectal cancer, NSCLC and glioma models [8, 10, 43, 74, 75] . Alternative inhibitory checkpoint molecules to PD-L1 may be upregulated within the TME and contribute to increasing resistance to treatment via induction of T-cell anergy [25, 26] . Whilst currently unknown, it may be possible for RT to upregulate other inhibitory checkpoint receptors such as Tim-3 and LAG-3, which could allow combined multiple ICI and RT combinations to increase the proportion of responders (Figure 1 ).
RT upregulates MHC expression and may increase neoantigen repertoire
Whilst it is known that RT can increase MHC-I expression in both a dose-and time-dependent manner in preclinical models [76] [77] [78] , understanding temporal changes in MHC expression before and following various therapies, as well as during tumour evolution itself, is poorly understood. A recently described anti-PD-1-resistant Kras-mutated, p53-deficient in vivo model demonstrated how radio-sensitisation is able to restore response to checkpoint blockade [75] . Interestingly, whilst PD-L1 expression was similar between parental and anti-PD-1-resistant lines, there was significant downregulation of MHC-I and -II in anti-PD-1-resistant tumours. Tumour irradiation lead to IFN-dependent upregulation of MHC-I expression and so this rate-limiting defect in antigen presentation and resistance to anti-PD-1 was restored [75] . This finding remains to be validated in both clinical samples and other malignancies, but could represent a significant ability of RT to restore antitumour immunity (Figure 1) . However, as aforementioned, the IFN-dependent ability of RT to both restore MHC-I and upregulate PD-L1 expression means that sufficient tumour control may only be feasible when RT is combined with ICIs.
Whilst RT can induce random point mutations and doublestranded breaks in DNA, its impacts on the generation of targetable de novo neoantigens remain undefined. Formenti and Demaria first created an abscopal mammary tumour model where combination of localised RT to one tumour with Flt3-L injection resulted in tumour regression at both the irradiated and non-irradiated tumours [79] . This effect was abolished in nude mice deficient for T cells and strengthened the hypothesis that RT can result in antigen release, DC take-up of antigens and crosspresentation to T eff cells to bridge a systemic immune response. Postow et al. subsequently described a patient with melanoma who having progressed after anti-CTLA-4 therapy, responded systemically after irradiation of a paraspinal mass with one further dose of anti-CTLA-4 [61] . Antibodies to NY-ESO-1, a cancer/testis antigen expressed in up to 40% of patients with advanced melanoma, were measured before and after anti-CTLA-4 and RT. RT resulted in a 30-fold rise in antibodies against epitopes to the NY-ESO-1 protein, with evidence of seroconversion to some epitopes [61] .
Finally, not all tumour mutations result in neoantigen generation, and as such, mutational load may not consistently represent an accurate surrogate of neoantigen burden except in tumours with the highest mutational loads. Additionally, it is unclear as to whether RT may increase neoantigen heterogeneity and therefore adversely affect long term outcomes such as those potentially seen following chemotherapy [37] , or whether the ability of RT to have other immunogenic properties outweighs this possibility.
RT modifies tumour metabolism and may synergise with ICIs and metabolic inhibitors
Acidification of the TME via a rising lactate level correlates with radioresistance [80] and is associated with reduced T eff activity and unaltered Treg activity [81] , as well as macrophage differentiation into a pro-metastatic M2 phenotype [54, 82] . This rise in acidification occurs within a hypoxic TME, and so strategies to restore normoxia or at least hypoxic metabolites may help to reinstate tumour control.
HIF-1 upregulates post-irradiation in response to TME hypoxia and ROS release, and can remain elevated for up to 1 week in preclinical models [72] . Bearing in mind that HIF-1a can cause upregulation of PD-L1 [51] , combination of RT with anti-PD-1/ anti-PD-L1 may have favourable metabolic consequences beyond the IFN-dependent cytotoxicity seen elsewhere [9] . Hypoxia is also able to upregulate PD-L1 on splenic myeloid-derived suppressor cells (MDSCs), macrophages, DCs and tumour cells and this process appears to be dependent upon HIF-1a [80] . Blocking PD-L1 in this preclinical model abrogated the immunosuppressive effects of MDSCs. With the knowledge that RT and anti-PD1/anti-PD-L1 can synergistically overcome adaptive upregulation of tumour cell PD-L1 [8, 9] , it is plausible that the additional combination of a HIF-1a inhibitor may enhance outcomes (Figure 1 ).
There is evidence to suggest that other metabolic checkpoints can be targeted therapeutically, such as 2-deoxyglucose (2DG) and IDO inhibitors. The glucose analogue 2DG is a glycolysis inhibitor and can result in cytotoxicity and radio-sensitisation in various models of NSCLC, pancreatic, cervical and glioma cancers [48, [83] [84] [85] . The combination of 2DG with RT has been studied in phase I/II clinical trials with moderate survival and quality of life benefits [71] . However, its effects in combination with ICIs or with both checkpoint blockade and RT remain unknown. IDO inhibitors have been combined with chemo-radiation in glioblastoma models, offering enhanced survival benefits associated with restoration of complement deposition [81] . The outcomes and mechanisms of targeting IDO inhibition in combination with RT and checkpoint blockade also remain to be elucidated.
Translating basic science into the clinic General considerations
Important practical considerations may ultimately be significant aspects that impact the efficacy of RT combined with immunotherapy. These include dose, fractionation and scheduling of RT with ICIs; volume of tumour irradiated; impact of involving regional lymph nodes in the RT field; optimum length of time to remain on checkpoint blockade following RT; and the optimal design of clinical trials (Table 2) .
Relevant preclinical considerations
There is some evidence to suggest that higher ablative doses of RT may stimulate stronger immune activation than conventional RT. Lugade et al. demonstrated in a preclinical melanoma model that 15 Gy single dose irradiation resulted in increased tumour immune cell infiltration than a fractionated (3 Gy Â5) schedule [86] . Additionally, a meta-analysis of nine preclinical studies identified that at a biological effective dose of 60 Gy, abscopal effects were seen in more than 50% of models [87] . Fractionation schedules varied, however, as did genetic backgrounds of mice, immune-competence and immunogenicity of models, and radiosensitivity of cell lines [87] . Conversely, a recent study demonstrated that higher single doses of RT from 12 to 18 Gy may hinder antitumour immunity. These higher doses of RT induced greater levels of Trex, a DNA exonuclease that degrades cytosolic DNA as part of the DNA damage repair pathway. As a result, IFN-b production was reduced and abrogated DC-mediated CD8þ T-cell priming, suggesting that RT doses below 12 Gy may be more immunogenic [88] .
RT fractionation and scheduling in combination with ICIs may also affect tumour control. Fractionated (but not single dose) RT in combination with anti-CTLA-4 has demonstrated tumour control at both locally irradiated and distant, non-irradiated sites of disease [60] . Notably, Dovedi et al. illustrated that concurrent RT and anti-PD-1 in a model of colorectal cancer resulted in improved antitumour effects [43] . Giving anti-PD-1 1 week after RT resulted in inferior outcomes compared with giving it on day 1 or 5 during RT. In contrast, the PACIFIC trial (locally advanced NSCLC) showed an 11-month improvement in median PFS when durvalumab (anti-PD-L1) was given up to 6 weeks sequentially following CRT [11] . This sort of discrepancy between preclinical and clinical studies highlights the need to further explore how RT/CRT can affect duration of PD-L1 expression, whether it is necessary to concurrently combine ICIs with RT possibly at the expense of additional toxicities, or whether we consider designing studies that compare concurrent versus adjuvant approaches.
These findings also raise important questions about whether exposure of an entire tumour to radiation is necessary, or if ablating larger versus smaller lesions (and in possibly different anatomical locations) is necessary to trigger an optimal systemic antitumour immune response in combination with ICIs. Additionally, delineating whether irradiating draining lymph nodes impacts T-cell-mediated immunity is of vital importance, particularly in NSCLC where thoracic lymph node irradiation is common practice. Considering that naïve T cells residing in lymph nodes may potentially possess tumour antigen specificity, their ablation could result in the bypass of DC-mediated activation within lymph nodes (Table 2) . Clearly, such questions require further interrogation across preclinical models utilising small animal radiation research platforms with subsequent translation into human trials.
Clinical considerations
Stereotactic ablative RT (SABR) is a technological advancement that delivers higher doses of RT, using a hypofractionated schedule and with greater conformity. Thus, SABR reduces normal tissue toxicity and improves control of the primary tumour [89] . SABR is standard of care treatment in early medically inoperable NSCLC and is being investigated in the oligometastatic setting. In a second-line phase II study of synchronous oligometastatic NSCLC (three or fewer metastatic lesions), patients who underwent aggressive surgical resection or CRT (including SABR in 48% of cases) of all lesions had an 8-month improvement in median PFS compared with patients managed with standard maintenance systemic therapy or observation [90] . This raises the question as to whether we should consider treating multiple metastatic lesions as opposed to searching for incredibly rare 'abscopal' effects. Additionally, pulsing RT to new metastatic lesions in combination with ICIs could potentially increase neoantigen release and improve ICI efficacy.
NSCLC is a suitable malignancy to begin investigating how SABR may affect immune readouts versus conventional RT, both separately and in combination with immunotherapies. Given the limited but interesting preclinical evidence to date that suggests that ablative RT may be more immunogenic than conventional RT [86, 87] , further evidence is required to elucidate whether SABR in combination with ICIs has superior immune-priming capability. Furthermore, whilst SABR can avoid irradiation of draining lymph nodes, it is unclear whether this translates into improved T-cell-mediated immunity (Table 2) .
A range of NSCLC clinical trials currently in setup or actively recruiting are assessing the efficacy of RT combined with anti-PD-1 (Table 3) . However, very few of these trials will compare scheduling of RT, SABR versus conventional RT, volumes of RT fields, or whether these combinations are more effective in early SABR, stereotactic ablative radiotherapy; CRT, chemoradiation; NS, not specified; WBRT, whole brain RT; IT, immunotherapy; ADV/HSV-tk, adenovirus-mediated expression of herpes simplex virus thymidine kinase.
versus later stage NSCLC. Additionally, there is currently no consensus on whether anatomical location of RT (e.g. visceral tissue, brain or bone) affects the immunogenic priming signal created. These sorts of considerations could greatly impact immune readouts (Table 2) . It would be pertinent to investigate whether the generation of de novo tumour antigens can be amplified by administering RT before or during use of immunotherapy. Perhaps one approach is to employ the use of window studies to investigate early temporal biopsy changes and potential biomarkers of response or resistance (Table 2) . However, repeat biopsies are a consistent challenge in NSCLC, given that this group of patients tends to have multiple smoking-related comorbidities and background underlying lung disease. This strengthens the need to prioritise assessment of circulating tumour cells and/or tumour DNA in the form of 'liquid biopsies'; progress may allow us to identify patients who may benefit from ICIs following RT/CRT. For example, Chaudhuri et al. recently demonstrated molecular residual disease using circulating tumour DNA in localised lung cancer and were able to detect patients who had favourable responses to ICIs and tyrosine kinase inhibitors [91] .
Discussion Conclusions
Despite the excitement generated by ICIs in the treatment of lung cancer, the majority of patients still fail to respond. Therefore, alterative therapeutic approaches are required to augment and drive antitumour responses in those patients who currently are not responding. RT offers the possibility of enhancing the number of clinical responses in combination with anti-PD-1/anti-PD-L1 by upregulating tumour PD-L1 and MHC-I expression, inducing ICD, and driving polyclonal T-cell responses. Evaluation of changes in immune-cell infiltration, neoantigen generation, MHC expression, IFN signalling, and tumour and Tcell metabolism is beginning to help our understanding of the dynamics of antitumour control following immune checkpoint blockade. Further optimising the clinical management of NSCLC will involve evaluation of how these factors change following RT, both alone and in combination with anti-PD-1/anti-PD-L1. Future progress in this field is likely to involve modifying NSCLC clinical trial design to account for variations in RT dose, fractionation, field volume and scheduling with ICIs, which may directly affect the nature of systemic antitumour immunity and clinical responses. Incorporation of insights learnt from preclinical studies to directly inform clinical trial design alongside focused translational research on developing predictive and prognostic immune biomarkers beyond PD-L1 expression is urgently required.
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